Revvity, Inc.
Orin's own judgment of how firmly the evidence points one way — not the chance the price goes up.
Revvity's operational turnaround remains real but slow: FY2025 revenue grew 3.7% with gross margin expanding to 53.1% from 48.0%, and the company has beaten consensus EPS in each of the last eight quarters, most recently by 16.5% (actual $1.41 vs. $1.21 estimated, period ended 4 Aug).
However, at $152.89 as of 30 Sep the stock trades at 72.7x trailing earnings — a 569% premium to the peer median of 10.9x — while FY2025 diluted EPS fell 13.7% to $2.08 and operating margin compressed to 12.5% from 14.9%. With RSI at 74.9 and the price roughly 45% above its 200-day moving average of $105.75 after hitting a fresh 52-week high, the rally has outrun the earnings trajectory, keeping risk/reward balanced rather than attractive.
What could go wrong
- Extreme valuation. P/E of 72.7x is 569% above the peer median of 10.9x, and EV/EBITDA of 25.2x is 111% above the peer median of 11.99x; any growth disappointment would be punished severely.
- Margin compression. FY2025 operating margin fell to 12.5% from 14.9% in FY2024, and net income declined 18.3% year over year despite revenue growth of 3.7%.
- Overbought technicals. RSI-14 at 74.9 as of 30 Sep with the stock at $152.89 versus a 50-day moving average of $126.28 and 200-day of $105.75 leaves the price extended and vulnerable to a pullback.
- China and margin pressure. Recent coverage (Zacks, 29 Sep) flags China exposure and margin pressures as near-term challenges to the diagnostics and life sciences outlook.
What would change my mind
Where this comes from: FY25 fundamentals · earnings vs estimates · peer comparison · technicals. Orin's read on RVTY; not advice.
How has the share price moved?
Up 66.6% over twelve months, from $97.16 on 27 Oct 2025 to $161.86 at the Tue 27 Oct 2026 close. That is its highest close in that time.
- Green line: the closing price each trading day.
- Grey line: the average closing price over the last 50 trading days.
- Dashed amber line: the same over the last 200 trading days — a slower, smoother line.
- Bars along the bottom: shares traded each day — green when it closed higher than the day before, rose when lower (the most, 12.3M, on 24 Nov 2025).
- Flags: the company's filings, on the day they were made (a 10-Q is the quarterly report and a 10-K the annual report; an 8-K reports a major event).
On file
All RVTY filings| Form | Filed | What it says | Read |
|---|---|---|---|
| 13G/A | 7 Oct | — | on file |
| 13G/A | 8 Sep | — | on file |
| 13G/A | 14 Aug | — | on file |
| 13G/A | 14 Aug | — | on file |
| 10-Q | 11 Aug | Total revenue was $729.7 million for the three months ended July 5, 2026, an increase of 1% year-over-year, driven by a 5% increase in Diagnostics segment revenue to $371.0… | read |
| 8-K | 4 Aug | Revvity, Inc. entered into a definitive agreement on July 31, 2026, to divest its Immunodiagnostics business in China (China IDX) for up to $200 million, subject to adjustments and conditions. | read |
| 13G/A | 15 May | — | on file |
| 10-Q | 12 May | Revvity’s first-quarter 2026 revenue rose 7% year-over-year to $711 million, driven by 8% growth in Diagnostics and 6% in Life Sciences, but consolidated gross margin compressed… | read |
Largest holders · 13F Q2 2026
Money flow| Filer | Position | Of fund |
|---|---|---|
| EdgePoint Investment Group | $950.7M | 7.2% |
| BlackRock | $852.1M | 0.0% |
| Vanguard Capital Management | $812.3M | 0.0% |
| T. Rowe Price Associates | $615.4M | 0.1% |
| Vanguard Portfolio Management | $530.8M | 0.0% |
| State Street | $483.2M | 0.0% |
| Geode Capital Management | $328.2M | 0.0% |
| Morgan Stanley | $286.5M | 0.0% |
| Invesco | $269.8M | 0.0% |
| Citadel Advisors | $162.1M | 0.0% |
70 of the 815 filers we track · quarter ended Q2 2026 · positions, not flows
Insiders, last 24 months: 109 Form 4 filings; open-market trades net −$6.1M. Of the 50 on hand, 0 were open-market purchases and 7 sales — the rest are grants, option exercises and tax withholding.
Ask Orin about RVTY
Orin answers questions about RVTY from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.
Start 3 free days →How is it priced, against its own past and its sector?
Priced at 77.1× its last 12 months of profit (Tue 27 Oct close) — higher than in all 4 of its last 5 fiscal years with a P/E (middle 38.6×); the typical Healthcare company on the NYSE is at 25.8×.
| Measure | Now | Its usual | Sector |
|---|---|---|---|
| P/E | 77.1×above usual | 38.6× | 25.8× |
| P/S | 6.20×above usual | 4.96× | — |
| EV/EBITDA | 26.6×above usual | 18.5× | — |
| P/B | 2.5×above usual | 1.8× | — |
- "Its usual" is the middle of its own last 5 fiscal years.
P/E: the share price divided by one year of profit per share — roughly how many years of today's profit the price pays for. A company that loses money has no P/E.
P/S: the company's total market value divided by one year of revenue. Used when there is no profit to measure.
EV/EBITDA: the price of the whole company (its shares plus its debt, minus its cash) divided by one year of operating profit before interest, tax and write-downs.
P/B: the share price divided by the book value per share — what the company owns minus what it owes, as its accounts record it. When book value is tiny, P/B swings wildly and says little.
What do the analysts who cover it publish?
The analysts' average 12-month price target is $132 (from $100 to $165) — 18% below the Tue 27 Oct close price. That is their published opinion, not Orin's.
$132
$100 – $165 · −18% against the last close
- 6 buy or overweight
- 6 hold
- 0 underweight or sell
Price target: the share price an analyst publishes for about 12 months ahead. It is the opinion of the firm that wrote it; the average is across the firms that cover the company.
Overweight / underweight: analysts' rating words: overweight means the firm expects the stock to do better than the others it covers, underweight worse. Their words, not Orin's.
How is it priced next to the companies it is compared to?
Priced at 77.1× its last 12 months of profit; the middle P/E of the 7 companies it is compared to that made a profit is 37.9×.
| Company | Market value | P/E | EV/EBITDA | Gross margin | Net margin | ROE |
|---|---|---|---|---|---|---|
| RVTYRevvity, Inc. | $18B | 77.1× | 26.6× | 52.1% | 8.2% | 3% |
| AAgilent Technologies, Inc. | $50B | 34.9× | 25.7× | 53.7% | 19.5% | 20% |
| CRLCharles River Laboratories International, Inc. | $15B | 307× | 60.2× | 32.9% | 1.0% | 1% |
| DHRDanaher Corporation | $163B | 37.9× | 26.0× | 58.6% | 16.9% | 8% |
| MTDMettler-Toledo International Inc. | $34B | 36.3× | 27.1× | 59.0% | 22.2% | n/m |
| TECHBio-Techne Corporation | $11B | 62.1× | 33.3× | 65.8% | 15.0% | 9% |
| TMOThermo Fisher Scientific Inc. | $256B | 36.5× | 26.0× | 41.4% | 15.0% | 13% |
| WATWaters Corporation | $46B | 117× | 53.3× | 50.8% | 3.6% | 2% |
- MTD: return on equity is not meaningful (n/m) — book value is below zero.
- The list of companies is the data vendor's choice, so it can include a company a person would not have picked.
Market value: the share price times the number of shares — what the whole company is priced at.
P/E: the share price divided by one year of profit per share — roughly how many years of today's profit the price pays for. A company that loses money has no P/E.
EV/EBITDA: the price of the whole company (its shares plus its debt, minus its cash) divided by one year of operating profit before interest, tax and write-downs.
Gross margin: the share of each $1 of sales left after the direct cost of making what was sold.
Net margin: the share of each $1 of sales kept as profit after every cost. Below zero, the company lost money.
ROE: return on equity: one year of profit as a share of the shareholders' money in the business (its book value).
Is it priced high or low compared with its own past?
Priced at 77.1× its last 12 months of profit (Tue 27 Oct close). It has no full fiscal year on file since its history starts, so there is nothing of its own to compare with.
- Now77.1×
P/E: the share price divided by one year of profit per share — roughly how many years of today's profit the price pays for. A company that loses money has no P/E.
Fiscal year (FY): the company's own 12-month accounting year, which need not match the calendar year.
How has its sector been priced?
Healthcare companies on the NYSE were priced at a typical 25.8× their yearly profit (Tue 27 Oct close).
- Now25.8×
- Each year is the middle of that calendar year's daily sector P/E; "Now" is the Tue 27 Oct close figure, the same one in the table above.
Sector P/E: the middle P/E of the companies in the same sector on the same stock exchange, as the data vendor works it out each day.
What does a cash-flow model say a share is worth?
A standard cash-flow model puts it at $112 a share — 31% below the $161.53 price it was computed against (27 Oct).
| Model | Value a share | Against the price then |
|---|---|---|
| Standard | $112 | 31% below $161.53 |
| Levered | $62 | 62% below $161.53 |
Discounted cash flow: a model's estimate of what the company is worth today, from the cash it is forecast to make in future years. Small changes in the forecast move it a lot, and it says little about a company that loses money.
Standard / levered: two versions of the cash-flow model: the standard one counts the cash before the company pays its lenders, the levered one after.